Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebecca Matro

Gastroenterology Portland, OR Medical Doctor

NPI 1043484405 CMS profile 1290921

3181 Sw Sam Jackson Park Rd, L461, Portland, OR 97239

Open in the dashboard

General payments

$153,564

415 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$83 paid to institutions, not to them · program year 2019

Through program year 2025, Rebecca Matro of Portland, OR is reported in the CMS Open Payments database as having received $153,564 across 415 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $83 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,060 62
2024 General $61,998 104
2023 General $20,892 111
2022 General $17,180 80
2021 General $1,124 45
2020 General $294 8
2019 General $5,016 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Matro
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Rebecca Matro were reported at $47,060. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Rebecca Matro Gastroenterology median Middle half National median
2019 $5,016 $417 $126–$1,100 $163
2020 $294 $224 $74–$624 $114
2021 $1,124 $352 $106–$1,054 $132
2022 $17,180 $448 $129–$1,270 $149
2023 $20,892 $533 $150–$1,390 $160
2024 $61,998 $605 $160–$1,606 $164
2025 $47,060 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $86,931 93 payments
  2. AbbVie, Inc. $57,963 168 payments
  3. Pfizer Inc. $5,032 6 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $631 26 payments
  5. Celgene Corporation $542 20 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $528 26 payments
  7. Janssen Scientific Affairs, LLC $441 5 payments
  8. Regeneron Healthcare Solutions, Inc. $278 12 payments
  9. Merck Sharp & Dohme Corporation $264 14 payments
  10. Genzyme Corporation $261 9 payments
  11. Other $692 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $113,192 42 payments
  2. Consulting Fee $18,795 6 payments
  3. Travel and Lodging $11,390 45 payments
  4. Food and Beverage $10,187 322 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $82,613 77 payments
  2. STELARA $38,777 58 payments
  3. SKYRIZI Immunology $29,452 60 payments
  4. RINVOQ $21,504 57 payments
  5. SKYRIZI Immunology $6,029 9 payments
  6. XELJANZ $5,032 6 payments
  7. CREON $635 24 payments
  8. LINZESS $553 27 payments
  9. ZEPOSIA $514 18 payments
  10. XIFAXAN $491 24 payments
  11. Other $2,748 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

299

Median for Gastroenterology: 569

Drug cost

$1,090,680

Median for Gastroenterology: $104,976

Branded share of claims

55.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi On-Body Risankizumab-Rzaa Brand 28 $529,782
Stelara Ustekinumab Brand 11 $295,010
Rinvoq Upadacitinib Brand 29 $214,930
Mesalamine Generic 53 $28,239
Linzess Linaclotide Brand 19 $9,904
Motegrity Prucalopride Succinate Brand 12 $6,184
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 55 $3,743
Lubiprostone Generic 12 $1,690
Pantoprazole Sodium Generic 23 $410
Omeprazole Generic 32 $346

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$56,256

Medicare's payments for the services billed

Medicare patients

239

Average age 74

Services billed

936

150 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 50%
Ischemic heart disease 34%
Osteoporosis 28%
Diabetes 26%
Depression 26%
Heart failure 25%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $27,159
$27,159 — —
STELARA
  • Janssen Biotech, Inc. $16,591
  • Janssen Scientific Affairs, LLC $148
$16,739 11 —
SKYRIZI
  • AbbVie, Inc. $12,043
$12,043 28 —
RINVOQ
  • AbbVie, Inc. $5,212
$5,212 29 —
DUPIXENT
  • GENZYME CORPORATION $129
  • Regeneron Healthcare Solutions, Inc. $98
$227 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record